Comunicati stampa
Che si tratti di un nuovo prodotto a supporto di ricerche innovative, di una collaborazione strategica con un cliente o di una iniziativa benefica che supporta la nostra missione, abbiamo sempre qualcosa in corso. Qui di seguito troverai i nostri comunicati stampa più recenti e un filtro per velocizzare la tua ricerca.
Contatti
Soltanto per i giornalisti:
Rachel Bloom-Baglin
Telefono: +49 (6151) 72-44461
May 29, 2024
Merck Signs MoU with KAIST to Advance Scientific CollaborationMerck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST).
May 28, 2024
Merck Launches First Software for Complete Data Traceability in Microbial Quality ControlMerck, a leading science and technology company, has launched its M-Trace® Software & Mobile App, a comprehensive data tracking solution to digitize sterility testing.
May 22, 2024
Merck Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector ManufacturingMerck, a leading science and technology company, today announced the signing of a definitive agreement to acquire Mirus Bio for US$ 600 million.
Apr 17, 2024
Merck Inspires Students to Explore STEM Careers with 2024 Curiosity Cube TourMerck, a leading science and technology company, officially kicked off its global 2024 Curiosity Cube tour today in Darmstadt, Germany.
Apr 16, 2024
Merck Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety TestingMerck, a leading science and technology company, has launched the first all-in-one, validated genetic stability assay of its kind.
Mar 26, 2024
Merck Expands M Lab™ Collaboration Center in ShanghaiMerck, has expanded its M Lab™ Collaboration Center in Shanghai, the company’s largest in its global network of ten interconnected labs.
Mar 20, 2024
Merck Invests More than € 300 Million in New Life Science Production Site in KoreaMerck invests more than € 300 million into a new Bioprocessing Production Center in Daejeon, South Korea.
Feb 27, 2024
Merck Opens New € 20 Million Distribution Center in Brazil13,000 square-meters space for Life Science business sector accommodates 11,000 pallet positions and more than 50,000 stock-keeping units.
Jan 24, 2024
Merck Announces a Non-Binding MoU with Mycenax Biotech to Drive Innovation in Bioprocessing TechnologyMerck announced that the Life Science business sector entered into a non-binding MoU with Mycenax Biotech to explore cooperation to bring innovative and high-capacity bioprocessing solutions to Taiwan and other international markets.
Dec 05, 2023
Merck Launches First Ever AI Solution to Integrate Drug Discovery and SynthesisCombines generative AI, machine learning and computer-aided drug-design to increase the success rate of new drugs and therapies
Nov 21, 2023
Merck Expands Newest Biologics Testing Center in ShanghaiFurther develops its biosafety testing laboratories to meet local demand; new labs complete 2nd phase of company’s € 29 million Biologics Testing Center opened in 2022.
Nov 14, 2023
Merck Launches ChemisTwin™, First Ever Digital Reference Materials Platform for Analytical TestingAccelerates digitalization in labs and manufacturing by offering traceable digital records of physical reference materials.
Sep 26, 2023
Merck to Become First Provider to Offer Fully Integrated mRNA ServicesMerck today became the first CTDMO to offer integrated services for all critical stages of mRNA development, manufacturing, and commercialization, including products and testing.
Jul 12, 2023
Merck Invests € 23 Million to Expand Cell Culture Media Production in Kansas, USALenexa, Kansas, USA facility becomes company’s largest dry powder cell culture media facility and Center of Excellence
Jun 29, 2023
Merck Invests Approximately € 70 Million to Expand Reagent Manufacturing in ChinaMerck is expanding production capacity for highly purified reagents with a € 70 million investment at Nantong, China manufacturing site.
Jun 06, 2023
Merck Announces Proteologix as Winner of its North American Advance Biotech GrantMerck announced that Proteologix US Inc. (“Proteologix”) has been selected as the North American winner of its 12th Advance Biotech Grant program.
May 31, 2023
Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine ManufacturersAccording to a recent study sponsored by Merck, a leading science and technology company, mRNA technology is a “game-changer” for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey.
May 31, 2023
Merck Increases Global Commitment to Biosafety Testing With € 35 Million Investment in ScotlandResponds to global demand for biosafety testing for drug development and commercialization. Expansion creates nearly 500 new jobs in Glasgow and Stirling. Company’s investment to boost global testing capacity now tops € 350 million since mid-2022.
May 02, 2023
Merck Signs MoU for New BioProcessing CenterMerck partners with MOTIE and Daejeon City for a new Asia-Pacific BioProcessing Center to advance life science.
Apr 26, 2023
Merck Kicks Off 2023 Curiosity Cube Mobile Lab TourOver 250 events expected to reach more than 45,000 future scientists on two continents. Hands-on experiments to focus on the impact of contamination on the planet and everyday life.
Apr 24, 2023
Merck Launches Ultimus® Film to Offer Superior Strength and Leak Resistance in Single-use AssembliesMerck, a leading science and technology company, today announced the launch of its Ultimus® Single-Use Process Container Film.
Mar 27, 2023
Merck Announces Expanded Partnership with Beyond Benign to Increase Global Access to Green Chemistry EducationPartnership to support Beyond Benign’s online learning platform and higher education program
Dec 07, 2022
MoU: Merck & Synplogen for Gene TherapyNon-binding MoU signed between Merck and Synplogen for collaborative initiatives.
Dec 06, 2022
Merck Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems AcquisitionMerck, a leading science and technology company, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.
Nov 16, 2022
Merck Invests € 290 Million in U.S. Drug Safety Testing CapacityMerck invests more than € 290 million in its biosafety testing capacity at Rockville, Maryland, USA.
Nov 07, 2022
Merck Announces Collaboration with Biotheus to Accelerate Drug Submission and Approval Process for Biopharmaceutical Industry in ChinaMerck, a leading science and technology company, today announced a collaboration with Biotheus.
Oct 04, 2022
Merck Boosts Commercial Capacity in France as Part of New Millipore® CTDMO ServicesThe Life Science business of Merck has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France.
Sep 21, 2022
Merck Announces Opening of New € 29 Million Biologics Testing Center in ShanghaiMerck, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the opening of a viral clearance (VC) laboratory as part of the first building phase of its new € 29 million China Biologics Testing Center.
Sep 08, 2022
Merck Invests More Than € 130 Million to Strengthen Manufacturing Capabilities in Molsheim, FranceMerck, a leading science and technology company, strengthens its manufacturing capabilities for single-use assemblies
Aug 08, 2022
Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production PlatformMerck, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral vector manufacturing offering.
Jul 19, 2022
New Solar Panels at Merck’s Wisconsin, USA Site Add Renewable Energy to Power Grid7,000 solar panels produce energy to power 700 homes, Part of We Energies’ “Solar Now” program, bringing more renewable energy to Wisconsin, Reinforces the company’s long-term commitment to renewable energy.
Jul 18, 2022
Life Science Business of Merck Breaks Ground on Company’s First Lateral Flow Membrane Production Facility in the United StatesNew facility to manufacture the company’s Hi-Flow™ Plus lateral flow membrane used in rapid diagnostic test kit manufacturing, including Covid-19.
Jun 21, 2022
Merck Opens €59M CDMO Facility for Cancer TherapiesMerck doubles high-potent active pharmaceutical ingredients (HPAPI) production capacity at Verona, Wisconsin facility.
Jun 14, 2022
Merck Announces Collaboration with Agilent Technologies to Fill Industry Gap in Process Analytical Technologies for Downstream ProcessingMerck collaborates with Agilent Technologies to advance Process Analytical Technologies (PAT).
May 23, 2022
Merck Invests More Than €440 Million and Expands its Membrane and Filtration Manufacturing in IrelandThe investment, which is the largest in a single site ever for the Life Science business sector, significantly increases membrane manufacturing capacities and enables the construction of a new filtration manufacturing facility.
May 18, 2022
Merck Announces the Expansion of Hands-On Science Education Program with Kick-off of Global Curiosity Cube® Mobile LabMerck today announced that the Life Science business further enhanced its commitment to Science, Technology, Engineering and Math (STEM) education, with the launch of its 2022 Curiosity Cube® mobile science lab in Europe and North America.
Apr 28, 2022
Merck Announces Investment of Approximately € 100 Million to Accelerate Single-Use Manufacturing in ChinaMerck’s First Asia Pacific Mobius® Single-Use Manufacturing Center in Wuxi, China
Apr 21, 2022
Merck Transforms Media Preparation and Dispensing with New ReadyStream® SystemReadyStream® system offers automated media preparation to conveniently provide a large volume of preheated media, eliminates five time-consuming steps.
Apr 14, 2022
Merck’s ZooMAb® Antibodies Earns First-Ever ACT Label from My Green LabZooMAb® antibodies first-ever antibody to be recognized for low-environmental impact by My Green Lab
Apr 05, 2022
Merck Announces Acquisition of MAST® Platform from Lonza, a Leading Automated Bioreactor Sampling System to Advance BioProcessing CapabilitiesMerck to become the first company to offer a fully integrated ecosystem for advanced process technologies.
Feb 22, 2022
Merck Renewable Energy InitiativeMerck, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash. The business combination is expected to enable the Life Science business to provide its customers with comprehensive end-to-end contract development and manufacturing organization (CDMO) services across the mRNA value chain. The Life Science business plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years.
Feb 15, 2022
Merck and Waters to Collaborate on Extractables and Leachables Reference LibraryMerck's Life Science business sector has entered into a collaboration with Waters Corporation to build and expand an Extractables and Leachables (E&L) Reference Library to include ion mobility measurements
Feb 07, 2022
Merck Announces Organizational Transformation to Strengthen CDMO Offering and Accelerate Future GrowthMerck today announced several organizational changes and a new operating model to support the long-term growth strategy of the Life Science business sector and to better serve the evolving needs of its global customers.
Jan 26, 2022
Merck Announces MoU with ID Pharma to Accelerate Development and Manufacturing of Gene TherapyMerck, a leading science and technology company, today announced that the Life Science business sector signed a non-binding Memorandum of Understanding (MoU) with ID Pharma, the advanced medical business within I’rom Group, outlining its planned support of the development and manufacturing of leading-edge gene therapy.
Mar 03, 2020
Merck’s New LANEXO® System to Improve Scientists’ Productivity in the LabMerck today launched its LANEXO® Lab Inventory, Safety and Compliance Management System, a new digital laboratory informatics solution designed to drastically reduce time in labs and improve data quality and traceability.
Dec 10, 2018
Merck and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent ModelsMerck, a leader in genome editing, today announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway.
Per continuare a leggere, autenticati o crea un account.
Non hai un Account?
